leisure time -WSS

leisure time

author：hotspot 2025-09-06 04:40:49 - browse：2389

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： The pink breast cancer awareness ribbon needs a redesign

WSS

Diversifying clinical trials isn't enough to close racial gaps: study

New lawsuit accuses health insurer Cigna of denying claims in bulk

First Opinion Podcast: How to protect health care in times of war

Truvian presents data for its desktop blood

Readout Newsletter: New research from Sanofi, Regeneron, etc.

A new crop of companies is reshaping the health data economy

focus

leisure time

leisure time

Heart attack and stroke risk calculators need revising

Why patients can’t get everything they want on drug pricing

Malaria cases in Florida and Texas: Here’s what you need to know

In the gardens at Boston Children's Hospital, families find sanctuary

BioMarin wins approval for gene therapy to treat hemophilia A

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Continuity nursing helped my family in our darkest PICU moments

A new crop of companies is reshaping the health data economy

BioMarin wins approval for gene therapy to treat hemophilia A

Rise in cancer among younger people worries and puzzles doctors

focus

Paying for Covid pills will soon shift to insurers

Will the FTC rein in IQVIA's health data empire?

Medtronic CEO on promising devices for diabetes, hypertension

STAT Report: Patient voices and perspectives

Why patients can’t get everything they want on drug pricing

Senate panel to vote on hospitals, PBMs, prisoner care

hotspot

leisure time

explore

knowledge